George Eric Davis - 28 May 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
28 May 2024
Net transactions value
-$466,167
Form type
4
Filing time
30 May 2024, 18:18:05 UTC
Previous filing
06 May 2024
Next filing
27 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $2,577,635 +40,850 +73% $63.10 97,007 28 May 2024 Direct F1
transaction BMRN Common Stock Sale $2,834,576 -38,071 -39% $74.46 58,936 28 May 2024 Direct F1, F2
transaction BMRN Common Stock Sale $209,225 -2,779 -4.7% $75.29 56,157 28 May 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -40,850 -100% $0.000000* 0 28 May 2024 Common Stock 40,850 $63.10 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on September 13, 2023.
F2 The price in column 4 is the weighted average price. The purchase price actually received ranged from $74.12 to $74.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3 The price in column 4 is the weighted average price. The purchase price actually received ranged from $75.00 to $75.735. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.